Introduction
============

Metachondromatosis (MC) is a rare skeletal disorder[@R1]^-^[@R3] characterized by cartilaginous cysts (enchondromas) and osteocartilaginous exostosis-like lesions (osteochondromas).[@R4]^,^[@R5] The enchondromas in MC mainly affect the iliac crests and metaphyses of tubular bones of the lower extremities, while osteochondromas are typically seen in the hands and feet (primarily in the digits and toes). Occasionally, there is the vertebral and flat bone involvement,[@R6] and avascular necrosis of the femoral epiphysis is another common feature.[@R7] These lesions can regress spontaneously[@R8] or transform to chondrosarcoma.[@R9] The actual prevalence of MC is unknown, although more than 30 cases have been reported. Diagnosis is made on the basis of clinical signs, radiographic findings and familial history,[@R8] and treatment relies primarily on surgical intervention to ameliorate symptoms and/or skeletal deformity.[@R4]^,^[@R5]

MC was known to show autosomal dominant inheritance, but the molecular basis for this skeletal disorder had been obscure. Recently, mutations in the *PTPN11* gene (located on 12q24) were linked to MC.[@R1]^,^[@R2] *PTPN11* encodes SHP2, one of two vertebrate Src homology-2 domain containing PTPs. SHP2 is expressed ubiquitously and is required for RAS/ERK pathway activation in most RTK, cytokine receptor and integrin signaling pathways.[@R10]^,^[@R11] The RAS/ERK pathway regulates a broad spectrum of biological responses including, but not limited to, cell viability, proliferation, differentiation and migration. Not surprisingly, alterations in RAS/ERK pathway function contribute to various diseases, affecting multiple organs and tissues.[@R12]^,^[@R13]

The *PTPN11* mutations reported in MC families include deletions, nonsense mutations and splice site mutations.[@R1]^,^[@R2] In contrast to the gain-of-function *PTPN11* mutations associated with other human neoplasms (e.g., juvenile myelomonocytic leukemia (JMML), acute myelogenous (AML) and lymphoblastic leukemia (ALL), neuroblastoma and other solid tumors),[@R14] MC mutations result in functionally null alleles and represent a new category of human disease-associated *PTPN11* mutations. Intriguingly, we found that transgenic mice lacking Shp2 in a specific subset of chondroid progenitor cells recapitulate most of the features of MC.[@R15] Our mouse MC model, along with published data in human MC, establishes an important role for SHP2 in cartilage development and homeostasis. These studies also provide the first insight into PTP function in this cell type, in contrast to the well-studied roles for specific RTKs in this system.

*PTPN11* Mutations in Metachondromatosis
========================================

*PTPN11* is essential for the development and/or homeostasis of multiple organs/tissues. Global *Ptpn11* deletion results in early embryonic lethality.[@R16]^,^[@R17] Germ line and somatic mutations in *PTPN11* have been identified and linked with human diseases.[@R10]^,^[@R11]*PTPN11* mutations that encode catalytically defective (but not inactive) forms of SHP2 and impair the activation of the RAS/ERK signaling pathway cause LEOPARD syndrome (LS),[@R18] a rare genetic disorder characterized by lentigines, ECG abnormalities; ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retarded growth and deafness. In contrast to LS mutations, *PTPN11* mutations that lower the threshold for activation of SHP2 cause Noonan Syndrome (NS),[@R19] which typically presents with some combination of facial abnormalities, short stature, heart defects, cognitive deficits, bleeding problems and/or skeletal malformations. NS-associated SHP2 mutants increase RAS/ERK signaling in several different cell types/tissues, which result in the observed phenotypic abnormalities.[@R20]^-^[@R22] Somatic *PTPN11* mutations that cause constitutive activation of SHP2 contribute to the pathogenesis of certain types of myeloproliferative disorders and leukemias, most prominently JMML, but also AML and ALL, as well as some solid tumors.[@R11]^,^[@R14]^,^[@R23]

The *PTPN11* mutations in MC are distinct from those seen in NS and LS. Using whole-genome sequencing and partial linkage analysis, Sobreira et al.[@R2] first reported that nonsense and deletion mutations that cause premature translation termination co-segregate with the MC phenotype. Shortly thereafter, additional heterozygous loss-of-function mutations in *PTPN11* were identified in MC patients by linkage analysis with high-density SNP arrays.[@R1] These included frameshift, nonsense and splice-site mutations, as well as deletions.[@R1] A diagram showing all mutations identified in human MC can be found in [Figure 1A](#F1){ref-type="fig"}. Clearly, their location and predicted effects on SHP2 suggested that MC arises from *PTPN11* loss-of-function/null alleles, which were not found in Ollier disease and Maffucci syndrome,[@R1] the other two cartilage tumor syndromes in human. However, whether *PTPN11* loss-of-function mutations exist in other cartilage neoplasms (e.g., chondrosarcomas) remains unknown.

![**Figure 1.** (**A**) PTPN11 mutations identified in MC patients. The locations of MC mutations in the corresponding SHP2 structure are indicated by red, blue and green colored lines, representing frameshift, nonsense and splice-site mutations, respectively. Predicted protein changes are indicated with arrows. Please see references [@R1] and [@R2] for original references. (**B**) Micro-CT and Faxitron images demonstrate the existence of osteochondromas and enchondromas (arrows) at hip, knee and ankles of 12-week-old mice lacking SHP2 in cathepsin K-expressing cells (CtskCre;Ptpn11fl/fl, Ctsk-KO) but not its littermate controls (CtskCre;Ptpn11fl/+, Ctsk-Control).](rdis-1-e26657-g1){#F1}

Cell-of-Origin of Metachondromatosis
====================================

The cell-of-origin for the osteochondroma(s) and enchondroma(s) in MC also had been unclear/controversial.[@R24] Anatomically, MC lesions appear adjacent to the growth plate, suggesting cells from the growth plate, periosteum, perichondrium, or groove of Ranvier as candidates. Osteochondromas morphologically resemble growth plate cartilage and preferentially occur at the metaphyses of tubular bones; hence, epiphyseal chondrocytes were assumed to be their cell-of-origin.[@R25] Indeed, Jones et al.[@R26] appeared to have proved this hypothesis by means of a mouse model in which *Ext1,* which encodes a glycosyltransferase involved in heparan sulfate (HS) biosynthesis, was deleted in Col2α1-expressing cells, but not periosteum. However, because that Col2α1 promoter also is active in cells residing in the groove, the involvement of groove cells in the initiation of osteochondromas was not excluded by these studies.[@R27]

In an attempt to study Shp2 function in osteoclast development in vivo using cathepsin K (Ctsk)-Cre-directed *Ptpn11* deletion, we unexpected observed large numbers of enchondromas and osteochondromas **(**[Fig. 1B](#F1){ref-type="fig"}**)**, a phenotype strongly resembling the clinical features of human MC. Further analysis demonstrated that the skeletal disease in these mutant mice was not transferrable by bone marrow transplantation, and thus could not arise from osteoclasts. Subsequent lineage tracing studies using *Rosa26LSLlacZ* and *Rosa26LSLYFP* alleles revealed the presence of a previously undefined subset of Ctsk-expressing cells residing in the groove of Ranvier. Moreover, the absence of Shp2 in these cells caused their excessive proliferation, chondrogenic differentiation and eventually, cartilage tumor formation. Phenotypically these cells shared markers for mesenchymal stem cells (MSC), such as CD44, CD90, Stro-1 and CD166 and, under appropriate conditions, could undergo differentiation into bone, fate and cartilage ex vivo.[@R15] Based on these properties, we proposed these cells be renamed "Cathepsin K-expressing Chondroid Progenitors" (CCPs). Much remains to be learned about the property and physiology of CCPs; in particular, it will be informative to define the relationship between CCPs and bona fide MSCs.

To ask whether growth plate chondrocytes participate in osteochondroma development, as reported by Jones et al.[@R26] for *Ext1* deletion, or enchondromas, we crossed our *Ptpn11* floxed allele to *Col2CreER^T2^* and *Col10a1-Cre* mice to delete *Ptpn11* specifically in proliferating (after tamoxifen induction) or hypertrophic chondrocytes, respectively. In marked contrast to the effects of Ctsk-Cre-evoked deletion, no osteochondromas were observed in mice lacking Shp2 in Col2α1-expressing cells over 6 mo of observation. Occasionally, solitary enchondromas developed in a few mice that lacked Shp2 in Col2α1- or Col10α1-expressing cells (Yu Y and Yang W, manuscript in preparation). Given that Ctsk^+^ groove of Ranvier cells could migrate into articular and growth plate cartilage, it is unclear whether those enchondromas arose from "native" physeal chondrocytes or from progeny of the Ctsk^+^ groove of Ranvier cells; further studies are needed to address these issues. Taken together, though, our data clearly show that the cell-of-origin for MC is CCPs, and the effects of *Ext1* and *Ptpn11* deletion suggest a different cell-of-origin for hereditary osteochromas and MC, respectively. It remains unclear (and an important topic for future research) whether *Col2α1-* and/or *Col10α1Cre*-expressing cells derive from Ctsk-Cre-expressing cells or represent a distinct lineage.

Molecular Pathogenesis of MC
============================

Perichondrial cells originate from the outer edges of the mesenchymal condensation, and these cells have distinct properties.[@R28]^,^[@R29] During skeletal development and homeostasis, perichondrial cells can send and receive signals from the adjacent growth plate. In turn, these signals can influence the perichondrium and surrounding chondroid cells.[@R28] The growth plate comprises cartilaginous cells in sequential resting, proliferating, pre-hyperthrophic and hyperthrophic stages. At the distal end of the plate, hypertrophic chondrocytes undergo apoptosis and serve as scaffolds to facilitate new bone formation by invading osteoblasts.[@R30] Skeletal growth is achieved by the progressive replenishment and replacement of the growth plate cartilage by chondrocytes and bone cells acting in concert.[@R31]^,^[@R32]

Enchondromas and osteochondromas arise at the nexus of the growth plate and epiphyseal cartilage of tubular bones, suggesting that deregulation of signaling pathways that modulate growth plate chondrocytes and perichondrial cells could contribute to the pathogenesis of these lesions.[@R25] Multiple signaling pathways, including the TGFβ, BMP, FGF, IGF1, IHH, PTHrP, and Wnt/β-catenin pathways, regulate chondrogenesis and endochondral bone formation.[@R31]^,^[@R33]^-^[@R37] Among these, the FGFR3, PTHrP and IHH signaling pathways are critical. FGF18 is expressed predominantly in the perichondrium and signals through FGFR3 and the ERK MAPK pathway to negatively regulate IHH expression by pre-hypertrophic and hypertrophic chondrocytes.[@R38]^,^[@R39] IHH, in turn, can induce PTHrP expression in the periarticular perichondrium. IHH signaling normally stimulates chondrocyte proliferation, whereas IHH/PTHrP, acting together, intitiate a negative feedback loop that inhibits the differentiation of proliferating chondrocytes and sustains their proliferation.[@R40] Enchondromas are assumed to result from a failure in terminal differentiation of growth plate chondrocytes,[@R25] a notion supported by the observation that constitutively active Hedgehog or PTHrP signaling causes enchondromas[@R41]^,^[@R42] and osteochondromas.[@R15] Moreover, altered HH signaling is observed in osteochondromas arising from mutations in *EXT1* or *EXT2*.[@R5]^,^[@R43] In the growth plate, FGF and IHH signaling are modulated by HS, and thus by EXT-1/2, which limit the range of the signal by restricting FGF and IHH diffusion, and thereby facilitate normal endochondrial bone formation. Any change in the strength or territory of FGF and IHH signaling can influence the polarization of physeal chondroid cells, allowing them to grow in the wrong direction or location. IHH signaling also is critical for ossification of the perichondrium, which couples chondrogenesis to osteogenesis[@R44] at the bony collar adjacent to the growth plate; hence, deregulated IHH signaling might also cause defective ossification of the perichondrium and facilitate osteochondroma outgrowth.

In the light of the requirement for SHP2 in RTK-evoked RAS/ERK pathway activation and the role of ERK in repressing IHH/PTHrP production, we suspected that defective Erk activation in CCPs lacking Shp2 might regulate *Ihh* production. Indeed, Erk activation was compromised in Shp2-deficient CCPs and in a chondroprogenitor cell line after *Ptpn11* knockdown; consequently, these cells showed increased *Ihh* and *PTHrP* expression and enhanced chondrogenic differentiation.[@R15] Collectively, our data demonstrate that deregulation of the IHH/PTHrP pathway due to SHP2 deficiency in CCPs contributes to MC development. However, we do not exclude the potential involvement of other signaling pathway(s) in MC pathogenesis; indeed, whether additional pathway(s) (e.g., Wnt/β-catenin signaling) contribute to the pathogenesis of MC remains an important topic for future research.

Hedgehog Pathway Antagonists for the Treatment of MC and Other Cartilage Tumors
===============================================================================

The HH proteins comprise a group of secreted proteins that regulate cell growth, differentiation and survival.[@R45] HH signaling is modulated by the Patched and Smoothened molecules, which together form a signaling complex that controls downstream targets such Gli family transcription factors. Abnormal HH signaling is implicated in the development of a variety of cancers, including cartilage tumors.[@R25]^,^[@R46]^-^[@R48] Elevated IHH production and IHH/PTHrP signaling are reported in enchondromas and osteochondromas,[@R49] and blockade of HH signaling in our mouse model of MC ameliorates the severity of the disease.[@R15] These findings strongly suggest that HH pathway antagonists could potentially be used to prevent and/or treat enchondromas and osteochondromas.

Several HH pathway inhibitors are in development as therapeutic agents.[@R50] These act on the proteins involved in HH pathway regulation (PTCH1, SMO and GLI). Some of these agents are undergoing pre-clinical or clinical studies as anti-cancer agents, particularly for Gorlin syndrome, an inherited tumor syndrome characterized by widespread basal cell carcinomas.[@R51] In our mouse model of MC, animals were treated with PF-04449913, a small molecule Smoothened inhibitor from Pfizer, to inhibit SMO activity and test whether HH pathway blockade could ameliorate symptom severity. Remarkably, this compound significantly slowed the progression of MC, reduced cartilaginous tumor burden and dramatically improved the mobility of affected mice.[@R15] While these findings are quite exciting, obviously, human clinical trials will be needed to test whether this compound (and/or others of its class) is effective in MC patients. Other candidates for future clinical trials include Novartis LDE-225, Millennium Pharmaceuticals TAK-441, Genentech IPI-926 and Bristol-Myers BMS-833923.[@R50] Given the importance of the HH pathway in normal embryonic and skeletal development, caution must be taken in administering these agents to children or pregnant MC patients. It could be difficult to obtain a therapeutic index, although notably, at the doses of PF-04449913 employed in our mouse MC studies[@R15] and those of IPI-926 for human basal cell carcinoma treatment,[@R52] linear growth was not affected, although there were some common adverse effects from the latter, including abdominal pain, diarrhea, hyponatremia and arthralgia.[@R52]

CCPs in Cartilage Development and Homeostasis
=============================================

Articular cartilage, when damaged by trauma or diseases such as OA, is difficult to repair due to its relative lack of blood vessels and low number of stem/progenitor cells. The ability of CCPs to migrate toward articular cartilage suggests a potential role in articular cartilage development, homeostasis and injury repair ([Fig. 2](#F2){ref-type="fig"}). Morko et al.[@R53] showed earlier that a low number of Ctsk^+^ cells exist in healthy articular cartilage of adult mice, and their number increased during OA progression, mainly in clusters of proliferating chondrocytes. Conceivably, Ctsk production by cells within these clusters could degrade extracellular matrix and contribute to OA pathogenesis. Alternatively, cluster formation could arise from a unique Ctsk^+^ subpopulation of stem cells/progenitors. This hypothesis are actually supported by the notion that stem cell-like progenitors present in adult articular cartilage and also in the OA cell clusters,[@R54]^,^[@R55] they coincidently express high level of stem cell markers, such as Stro1, VCAM-1 and Notch.[@R56] Intriguingly, migratory cartilage stem cells were recently reported to exist in OA cartilage; they resemble cells that are seen in the OA clusters.[@R57] The origin of these cells and whether they express Ctsk are unclear. Further characterization of CCP function during articular cartilage development, homeostasis and disease is clearly indicated.

![**Figure 2.** Location and potential functions of CCPs in epiphyseal cartilage Diagrams showing the location of perichondrial groove of Ranvier (G.R) (shaded in red) in the knee joint. CCPs and their differentiated progeny are denoted by dots of black and gray color, respectively. Note that CCPs reside primarily in the groove of Ranvier (i, black), but they can migrate toward, and live in, epiphyseal (ii) and articular cartilage (iii). In these alternative niches, they could either live quiescently (black) or undergo chondrocytic differentiation (gray) and replenish cartilage. We hypothesize that under physiological conditions, CCPs might be required for epiphyseal cartilage development and homeostasis. During cartilage injury (such as osteoarthritis and trauma) or disease conditions (mutations, etc.), these cells respond to pathogenic insults and start to expand to repair cartilage damage or cause tumorigenesis.](rdis-1-e26657-g2){#F2}

The groove of Ranvier is a wedge-shaped tissue surrounding the periphery of the epiphyseal cartilage. Previous studies suggested that it serves as a reservoir of cartilaginous stem cells/progenitors for the germinal layer of the growth plate[@R58] and possibly for the superficial layer of articular cartilage.[@R59] However, the number of these progenitors is low and no specific markers were available, making it hard to discern their function in chondrogenesis. Our identification of CCPs and the finding that these cells can expand and form cartilage in the absence of SHP2 raises the exciting possibility that manipulation of signaling pathway(s) in these cells could potentially be used to prevent and/or treat degenerative cartilage diseases and cartilage injury.

Historically we always gain more than we expect by studying rare diseases, particularly medications based on the discoveries from rare disease research.[@R29]^,^[@R60] Understanding the molecular and cellular mechanisms underlying MC development has led to the discovery of an important anti-oncogenic function for *PTPN11*, heretofore viewed as a proto-oncogene, in cartilage. The double-edged sword effects of *PTPN11* are determined by both the specific cell type and the particular "wiring" of the signaling pathways therein. In certain types of cartilaginous cells, *PTPN11* controls the threshold for IHH and PTHrP production to sustain normal chondrogenesis; in such cells, excessive IHH and PTHrP due to *PTPN11* inactivation can cause cartilage tumor formation. This finding could also be relevant to oncogenic mechanisms in other tissues and/or explain the effects of *PTPN11* deletion on tissues where HH signaling is particularly important (e.g., in nervous system development). The discovery of CCPs residing within the groove of Ranvier, and possibly in articular cartilage, could also shed new light on cartilage development/homeostasis and lead to novel therapeutic approaches to cartilage diseases.
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